AbbVie stock fell 10% after emraclidine, its drug for schizophrenia, failed during the final stages of its trials. The ...

Arcutis Biotherapeutics has returned an impressive +200% YTD, following the successful product launch of Zoryve. See why I rate ARQT stock as a Strong Buy.

Researchers conducted a nationwide cohort study using data from the Taiwan National Health Insurance database and the Taiwan ...

The New Jersey-based drugmaker is trying to get the courts’ backing to pay hospitals rebates for two drugs in the 340B drug ...

Researchers at the University of Massachusetts Amherst have invented a new, sprayable delivery system for psoriasis ...

According to a study published in Biomaterials Advances, scientists at the University of Copenhagen have developed a patch ...

Researchers have developed a patch for easier and more effective treatment of psoriasis. The method may also be used in treatment of other inflammatory skin diseases.

Researchers at the University of Copenhagen have developed a patch for easier and more effective treatment of psoriasis. The ...

Researchers used pharmacovigilance data to examine the onset of gastrointestinal adverse events associated with the use of biologic therapies for psoriasis.

Researchers from the National Defense Medical Center in Taiwan have identified an increased risk of psoriasis in patients ...

In an as-started analysis, the risk for psoriasis among patients with stage III/IV cancers was two- to three-fold higher among ICI users when compared against controls who received chemotherapy or ...

Medically reviewed by Doru Paul, MD To confirm a psoriasis diagnosis, your healthcare provider will check your skin and scalp ...